Clinical Trial Update: Long-Acting Injectable Risperidone in the Treatment of Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating long-acting injectable risperidone for schizophrenia and schizoaffective disorder has completed. Results were posted on December 20, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Risperdal Consta (risperidone long-acting injectable)

Snippet

Sponsor: US Department of Veterans Affairs | Conditions: Schizoaffective Disorder, Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2013-12-20